Bivalirudin or heparin for systemic anticoagulation during pediatric extracorporeal membrane oxygenation: Multicenter retrospective study

• Published in: Thrombosis research Vol. 229; pp. 178 - 186
• Main Authors: Hamzah, Mohammed, Seelhammer, Troy G., Beshish, Asaad G., Byrnes, Jonathan, Yabrodi, Mouhammad, Szadkowski, Adam, Lutfi, Riad, Andrijasevic, Nicole, Hock, Kristal, Worley, Sarah, Macrae, Duncan J.
• Format: Journal Article
• Language: English
• Published: United States Elsevier Ltd 01-09-2023
• Subjects: Anticoagulation; Bivalirudin; Heparin; Pediatric extracorporeal membrane oxygenation; Anticoagulation; Bivalirudin; Heparin; Pediatric extracorporeal membrane oxygenation
• ISSN: 0049-3848; 1879-2472
• DOI: 10.1016/j.thromres.2023.07.012

The objective of this study is to evaluate the outcomes of unfractionated heparin (UFH) compared to bivalirudin anticoagulation in pediatric ExtraCorporeal Membrane Oxygenation (ECMO).
A multicenter retrospective study, that included pediatric patients <18 years of age, who were supported on ECMO between June 2017 and May 2020. Patients treated with UFH were matched 2:1 by age and type of ECMO support to the bivalirudin group.
The bivalirudin group (75 patients) were matched to 150 patients treated with UFH. Baseline characteristics and comorbidities of the two groups were similar. Veno-Arterial ECMO was the most common mode (141/225 [63 %]) followed by extracorporeal cardiopulmonary resuscitation (48/225 [21 %]). Bivalirudin treatment was associated with lower odds of bleeding events (aOR 0.23, 95%CI 0.12–0.45, p < 0.001) and lower odds of thrombotic events (aOR 0.48, 95%CI 0.23–0.98, p = 0.045). Patients who received bivalirudin had lesser odds for transfusion with fresh frozen plasma, and platelets (aOR 0.26, CI 0.12–0.57, p ≤0.001 and aOR 0.28, CI 0.15–0.53, p < 0.001, respectively). After adjusting for the type of ECMO support and adjusting for age, bivalirudin was associated with a decrease in hospital mortality by 50 % compared to the UFH group (aOR 0.50, 95%CI 0.27–0.93, p = 0.028). Similarly, for neurological disability at time of discharge, bivalirudin was associated with higher odds of intact neurological outcomes compared to UFH (OR 1.99 [95%CI 1.13–3.51], p = 0.017).
This study demonstrated that effective anticoagulation can be achieved with bivalirudin, which was associated with lesser odds of bleeding events and utilization of blood products. Bivalirudin, in comparison with UFH, was associated with greater odds of hospital survival and intact neurological function at the time of discharge. A prospective randomized trial is required to validate the results of this study.
•Evaluate outcomes pediatric ECMO using bivalirudin compared to heparin.•Bivalirudin was associated with a decrease in mortality and bleeding.•A prospective randomized trial is required to validate the results of this study.